Table 1.
Demographic and clinical characteristics at baseline (efficacy population, n = 34).
| Overall population (n = 34) | |
|---|---|
| Age, years (mean ± SD) | 48.2 ± 13.33 |
| Female sex, n (%) | 24 (70.6) |
| White race, n (%) | 34 (100) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 3 (8.8) |
| Not Hispanic or Latino | 31 (91.2) |
| Weight, kg (mean ± SD) | 97.8 ± 27.41 |
| BMI, kg/m2 (mean ± SD) | 35.6 ± 9.75 |
| Etiology of CS, n (%) | |
| ACTH-dependent: CD or ectopic, n (%) | 27 (79.4) |
| ACTH, pmol/L (median [min, max]) | 14.0 (6.0, 28) |
| 24-h UFC, nmol/d (median [min, max]) | 357.4 (83.4, 2823.8) |
| Adrenal adenoma (unilateral), n (%) | 7 (20.6) |
| ACTH, pmol/L (median [min, max]) | 1.0 (1.0, 1.6) |
| 24-h UFC, nmol/d (median [min, max]) a | 156.1 (56.9, 2341.0) |
| Osteocalcin, µg/L, (mean ± SD) b | 11.0 ± 7.55 |
| Analysis cohorts | |
| Hypertension, n (%) | 23 (67.6) |
| 24-h SBP, mmHg (mean ± SD) | 138.3 ± 8.59 |
| 24-h DBP, mmHg (mean ± SD) | 87.0 ± 5.65 |
| Hyperglycemia, n (%) | 27 (79.4) |
| IGT, n (%) | 10 (37.0) |
| T2DM, n (%) | 17 (63.0) |
| Fructosamine, µmol/L (mean ± SD) | 225.3 ± 29.50 |
| Fasting plasma glucose, mmol/L (mean ± SD) | 6.6 ± 1.89 |
| 2-h oGTT plasma glucose, mmol/L (mean ± SD) | 12.7 ± 4.08 |
| AUCglucose, h•mmol/L (mean ± SD) | 26.2 ± 8.05 |
| HbA1c, % (mean ± SD) | 6.6 ± 1.26 |
To convert values of glucose to mg/dL, divide by 0.0555; UFC to µg/24 h, divide by 2.76.
a
Includes one patient with an adrenal adenoma who had a baseline 24-h UFC of 2,341 nmol/d (848.2 µg/d).
b
Osteocalcin n = 33.
ACTH, adrenocorticotropic hormone; AUC, area under the curve; BMI, body mass index; CD, Cushing disease; CS, Cushing syndrome; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; IGT, impaired glucose tolerance; oGTT, oral glucose tolerance test; SBP, systolic blood pressure; SD, standard deviation; T2DM, type 2 diabetes mellitus; UFC, urinary free cortisol.